Search
Search Results
-
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
BackgroundPalbociclib in combination with endocrine therapy is approved for treatment of hormone receptor-positive (HR+)/human epidermal growth...
-
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer
PurposePalbociclib has become the standard of care for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-)...
-
Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells
Senescent cells have a profound impact on the surrounding microenvironment through the secretion of numerous bioactive molecules and inflammatory...
-
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
PurposeData on treatments for male breast cancer patients are limited owing to rarity and underrepresentation in clinical trials. The real-world...
-
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper
CDK4/6 inhibitors plus endocrine therapy is a standard therapy for HR+/HER2- breast cancer. Herein, using structure-based drug design strategy, a...
-
A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases
BackgroundPalbociclib and abemaciclib are cyclin-dependent kinase (CDK) 4/6 inhibitors currently used to treat breast cancer. Although their...
-
Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells
Endocrine therapy plays a critical role in patients with hormone receptor-positive breast cancer. Endocrine-resistant breast cancer cells exhibit...
-
Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis
PurposeEndocrine therapy is the anti-tumor therapy for human breast cancer but endocrine resistance was a major burden. It has been reported that...
-
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
BackgroundMantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of...
-
Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study
BackgroundRetroperitoneal liposarcomas are locally aggressive and frequently recur following complete surgical resection. Palbociclib, a...
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
PurposeTo evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.
...
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care...
-
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Background and ObjectivesPalbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone...
-
Regression of choroidal metastasis from breast carcinoma with palbociclib
BackgroundUveal metastasis is reported to be the most common intraocular malignancy. The most common site of origin of ocular metastases in females...
